News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
206,209 Results
Type
Article (19800)
Company Profile (116)
Press Release (186284)
Multimedia
Podcasts (36)
Webinars (14)
Section
Business (63724)
Career Advice (831)
Deals (9019)
Drug Delivery (78)
Drug Development (18760)
Employer Resources (145)
FDA (3367)
Job Trends (6072)
News (95169)
Policy (7109)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1501)
Academic (2)
Accelerated approval (8)
Adcomms (16)
Allergies (29)
Alliances (17388)
ALS (55)
Alzheimer's disease (673)
Antibody-drug conjugate (ADC) (107)
Approvals (3483)
Artificial intelligence (254)
Autoimmune disease (49)
Automation (22)
Bankruptcy (51)
Best Places to Work (4890)
BIOSECURE Act (12)
Biosimilars (67)
Biotechnology (64)
Bladder cancer (48)
Brain cancer (15)
Breast cancer (197)
Cancer (1369)
Cardiovascular disease (151)
Career advice (750)
Career pathing (37)
CAR-T (97)
CDC (18)
Cell therapy (254)
Cervical cancer (10)
Clinical research (15241)
Collaboration (752)
Compensation (169)
Complete response letters (14)
COVID-19 (1005)
CRISPR (48)
C-suite (484)
Cystic fibrosis (53)
Data (1921)
Decentralized trials (1)
Denatured (23)
Depression (47)
Diabetes (135)
Diagnostics (2475)
Digital health (17)
Diversity (10)
Diversity, equity & inclusion (37)
Drug discovery (119)
Drug pricing (58)
Drug shortages (4)
Duchenne muscular dystrophy (78)
Earnings (15475)
Editorial (21)
Employer branding (23)
Employer resources (122)
Events (31067)
Executive appointments (562)
FDA (4246)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (6)
Funding (707)
Gene editing (86)
Generative AI (28)
Gene therapy (192)
GLP-1 (353)
Government (1398)
Guidances (121)
Healthcare (4955)
HIV (28)
Huntington's disease (22)
IgA nephropathy (23)
Immunology and inflammation (57)
Immuno-oncology (11)
Indications (28)
Infectious disease (1102)
Inflammatory bowel disease (77)
Inflation Reduction Act (8)
Influenza (39)
Intellectual property (63)
Interviews (118)
IPO (3664)
IRA (17)
Job creations (1312)
Job search strategy (638)
JPM (26)
Kidney cancer (2)
Labor market (81)
Layoffs (198)
Leadership (19)
Legal (1187)
Liver cancer (27)
Longevity (10)
Lung cancer (174)
Lymphoma (152)
Machine learning (19)
Management (43)
Manufacturing (312)
MASH (31)
Medical device (2670)
Medtech (2688)
Mergers & acquisitions (5760)
Metabolic disorders (345)
Multiple sclerosis (71)
NASH (9)
Neurodegenerative disease (121)
Neuropsychiatric disorders (21)
Neuroscience (1117)
Neurotech (1)
NextGen: Class of 2026 (2083)
Non-profit (1687)
Now hiring (64)
Obesity (176)
Opinion (128)
Ovarian cancer (36)
Pain (69)
Pancreatic cancer (46)
Parkinson's disease (88)
Partnered (21)
Patents (101)
Patient recruitment (117)
Peanut (15)
People (28009)
Pharmaceutical (25)
Pharmacy benefit managers (2)
Phase 1 (4467)
Phase 2 (6295)
Phase 3 (6028)
Pipeline (1531)
Policy (103)
Postmarket research (557)
Preclinical (2548)
Press Release (61)
Prostate cancer (65)
Psychedelics (27)
Radiopharmaceuticals (68)
Rare diseases (261)
Real estate (2554)
Recruiting (58)
Regulatory (5715)
Reports (39)
Research institute (1300)
Resumes & cover letters (108)
Rett syndrome (3)
RNA editing (9)
RSV (41)
Schizophrenia (55)
Series A (131)
Series B (87)
Service/supplier (7)
Sickle cell disease (38)
Special edition (10)
Spinal muscular atrophy (56)
Sponsored (17)
Startups (2016)
State (1)
Stomach cancer (6)
Supply chain (38)
Tariffs (16)
The Weekly (13)
Vaccines (305)
Venture capital (61)
Weight loss (108)
Women's health (36)
Worklife (18)
Date
Today (46)
Last 7 days (211)
Last 30 days (763)
Last 365 days (9582)
2026 (1037)
2025 (9683)
2024 (11409)
2023 (12960)
2022 (15532)
2021 (17646)
2020 (16253)
2019 (14977)
2018 (10826)
2017 (10292)
2016 (10168)
2015 (10848)
2014 (7991)
2013 (6928)
2012 (7378)
2011 (7571)
2010 (7044)
Location
Africa (330)
Alabama (34)
Alaska (4)
Arizona (89)
Arkansas (4)
Asia (11620)
Australia (2023)
California (3257)
Canada (1057)
China (297)
Colorado (163)
Connecticut (103)
Delaware (177)
Europe (30272)
Florida (491)
Georgia (92)
Hawaii (2)
Idaho (12)
Illinois (219)
India (35)
Indiana (266)
Iowa (12)
Japan (171)
Kansas (42)
Kentucky (12)
Louisiana (8)
Maine (7)
Maryland (321)
Massachusetts (2697)
Michigan (129)
Minnesota (171)
Mississippi (5)
Missouri (47)
Montana (5)
Nebraska (10)
Nevada (23)
New Hampshire (17)
New Jersey (985)
New Mexico (16)
New York (1133)
North Carolina (535)
North Dakota (9)
Northern California (1667)
Ohio (110)
Oklahoma (9)
Oregon (20)
Pennsylvania (538)
Puerto Rico (6)
Rhode Island (16)
South America (393)
South Carolina (8)
Southern California (1134)
Tennessee (61)
Texas (455)
United States (12290)
Utah (71)
Vermont (1)
Virginia (83)
Washington D.C. (32)
Washington State (262)
West Virginia (1)
Wisconsin (75)
Wyoming (1)
206,209 Results for "roivant sciences inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
February 8, 2026
·
20 min read
Press Releases
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
January 26, 2026
·
4 min read
Press Releases
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
December 11, 2025
·
7 min read
Press Releases
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
November 10, 2025
·
15 min read
Immunology and inflammation
Roivant, Pfizer’s Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected that the drug candidate could hit $2 billion in sales in 2032.
September 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
October 28, 2025
·
4 min read
Press Releases
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
August 12, 2025
·
15 min read
Press Releases
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
September 18, 2025
·
10 min read
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves’ Disease Patients
September 4, 2025
·
11 min read
1 of 20,621
Next
